Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 248

1.

Profile of a Novel Anionic Fluoroquinolone-Delafloxacin.

Tulkens PM, Van Bambeke F, Zinner SH.

Clin Infect Dis. 2019 Apr 8;68(Supplement_3):S213-S222. doi: 10.1093/cid/ciy1079.

2.

Temocillin plasma and pancreatic tissue concentrations in a critically ill patient with septic shock.

Ngougni Pokem P, Capron A, Wallemacq P, Tulkens PM, Van Bambeke F, Laterre PF.

J Antimicrob Chemother. 2019 Jan 14. doi: 10.1093/jac/dky565. [Epub ahead of print] No abstract available.

PMID:
30649374
3.

Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis.

Chalhoub H, Sáenz Y, Nichols WW, Tulkens PM, Van Bambeke F.

Int J Antimicrob Agents. 2018 Nov;52(5):697-701. doi: 10.1016/j.ijantimicag.2018.07.027. Epub 2018 Aug 3.

PMID:
30081137
4.

The Putative De-N-acetylase DnpA Contributes to Intracellular and Biofilm-Associated Persistence of Pseudomonas aeruginosa Exposed to Fluoroquinolones.

Khandekar S, Liebens V, Fauvart M, Tulkens PM, Michiels J, Van Bambeke F.

Front Microbiol. 2018 Jul 10;9:1455. doi: 10.3389/fmicb.2018.01455. eCollection 2018.

5.

Activities of Combinations of Antistaphylococcal Antibiotics with Fusidic Acid against Staphylococcal Biofilms in In Vitro Static and Dynamic Models.

Siala W, Rodriguez-Villalobos H, Fernandes P, Tulkens PM, Van Bambeke F.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00598-18. doi: 10.1128/AAC.00598-18. Print 2018 Jul.

6.

Temocillin dosing in haemodialysis patients based on population pharmacokinetics of total and unbound concentrations and Monte Carlo simulations.

Miranda Bastos AC, Vandecasteele SJ, Spinewine A, Tulkens PM, Van Bambeke F.

J Antimicrob Chemother. 2018 Jun 1;73(6):1630-1638. doi: 10.1093/jac/dky078.

PMID:
29579214
7.

Cellular Pharmacokinetics and Intracellular Activity of Gepotidacin against Staphylococcus aureus Isolates with Different Resistance Phenotypes in Models of Cultured Phagocytic Cells.

Peyrusson F, Tulkens PM, Van Bambeke F.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02245-17. doi: 10.1128/AAC.02245-17. Print 2018 Apr.

8.

Mitochondrial Alterations (Inhibition of Mitochondrial Protein Expression, Oxidative Metabolism, and Ultrastructure) Induced by Linezolid and Tedizolid at Clinically Relevant Concentrations in Cultured Human HL-60 Promyelocytes and THP-1 Monocytes.

Milosevic TV, Payen VL, Sonveaux P, Muccioli GG, Tulkens PM, Van Bambeke F.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01599-17. doi: 10.1128/AAC.01599-17. Print 2018 Mar.

9.

Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?

Delattre IK, Taccone FS, Jacobs F, Hites M, Dugernier T, Spapen H, Laterre PF, Wallemacq PE, Van Bambeke F, Tulkens PM.

Expert Rev Anti Infect Ther. 2017 Jul;15(7):677-688. doi: 10.1080/14787210.2017.1338139. Epub 2017 Jun 19.

PMID:
28571493
10.

Acquired resistance to macrolides in Pseudomonas aeruginosa from cystic fibrosis patients.

Mustafa MH, Khandekar S, Tunney MM, Elborn JS, Kahl BC, Denis O, Plésiat P, Traore H, Tulkens PM, Vanderbist F, Van Bambeke F.

Eur Respir J. 2017 May 19;49(5). pii: 1601847. doi: 10.1183/13993003.01847-2016. Print 2017 May.

11.

Salicylidene Acylhydrazides and Hydroxyquinolines Act as Inhibitors of Type Three Secretion Systems in Pseudomonas aeruginosa by Distinct Mechanisms.

Anantharajah A, Buyck JM, Sundin C, Tulkens PM, Mingeot-Leclercq MP, Van Bambeke F.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e02566-16. doi: 10.1128/AAC.02566-16. Print 2017 Jun.

12.

Pharmacodynamics of ceftazidime/avibactam against extracellular and intracellular forms of Pseudomonas aeruginosa.

Buyck JM, Luyckx C, Muccioli GG, Krause KM, Nichols WW, Tulkens PM, Van Bambeke F.

J Antimicrob Chemother. 2017 May 1;72(5):1400-1409. doi: 10.1093/jac/dkw587.

PMID:
28137941
13.

High-level resistance to meropenem in clinical isolates of Pseudomonas aeruginosa in the absence of carbapenemases: role of active efflux and porin alterations.

Chalhoub H, Sáenz Y, Rodriguez-Villalobos H, Denis O, Kahl BC, Tulkens PM, Van Bambeke F.

Int J Antimicrob Agents. 2016 Dec;48(6):740-743. doi: 10.1016/j.ijantimicag.2016.09.012. Epub 2016 Oct 19.

PMID:
28128097
14.

Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic.

Chalhoub H, Pletzer D, Weingart H, Braun Y, Tunney MM, Elborn JS, Rodriguez-Villalobos H, Plésiat P, Kahl BC, Denis O, Winterhalter M, Tulkens PM, Van Bambeke F.

Sci Rep. 2017 Jan 16;7:40208. doi: 10.1038/srep40208.

15.

The antifungal caspofungin increases fluoroquinolone activity against Staphylococcus aureus biofilms by inhibiting N-acetylglucosamine transferase.

Siala W, Kucharíková S, Braem A, Vleugels J, Tulkens PM, Mingeot-Leclercq MP, Van Dijck P, Van Bambeke F.

Nat Commun. 2016 Nov 3;7:13286. doi: 10.1038/ncomms13286.

16.

Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe.

Mustafa MH, Chalhoub H, Denis O, Deplano A, Vergison A, Rodriguez-Villalobos H, Tunney MM, Elborn JS, Kahl BC, Traore H, Vanderbist F, Tulkens PM, Van Bambeke F.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6735-6741. doi: 10.1128/AAC.01046-16. Print 2016 Nov.

17.

Subcellular mechanisms involved in apoptosis induced by aminoglycoside antibiotics: Insights on p53, proteasome and endoplasmic reticulum.

Denamur S, Boland L, Beyaert M, Verstraeten SL, Fillet M, Tulkens PM, Bontemps F, Mingeot-Leclercq MP.

Toxicol Appl Pharmacol. 2016 Oct 15;309:24-36. doi: 10.1016/j.taap.2016.08.020. Epub 2016 Aug 26.

PMID:
27568863
18.

Inhibition of the Injectisome and Flagellar Type III Secretion Systems by INP1855 Impairs Pseudomonas aeruginosa Pathogenicity and Inflammasome Activation.

Anantharajah A, Faure E, Buyck JM, Sundin C, Lindmark T, Mecsas J, Yahr TL, Tulkens PM, Mingeot-Leclercq MP, Guery B, Van Bambeke F.

J Infect Dis. 2016 Oct 1;214(7):1105-16. doi: 10.1093/infdis/jiw295. Epub 2016 Jul 13.

PMID:
27412581
19.

Molecular Analysis of Rising Fluoroquinolone Resistance in Belgian Non-Invasive Streptococcus pneumoniae Isolates (1995-2014).

Ceyssens PJ, Van Bambeke F, Mattheus W, Bertrand S, Fux F, Van Bossuyt E, Damée S, Nyssen HJ, De Craeye S, Verhaegen J; Belgian Streptococcus pneumoniae Study Group, Tulkens PM, Vanhoof R.

PLoS One. 2016 May 26;11(5):e0154816. doi: 10.1371/journal.pone.0154816. eCollection 2016.

20.

Modulating antibiotic activity towards respiratory bacterial pathogens by co-medications: a multi-target approach.

Vandevelde NM, Tulkens PM, Van Bambeke F.

Drug Discov Today. 2016 Jul;21(7):1114-29. doi: 10.1016/j.drudis.2016.04.001. Epub 2016 Apr 16. Review.

PMID:
27094105
21.

The role of solithromycin in the management of bacterial community-acquired pneumonia.

Van Bambeke F, Tulkens PM.

Expert Rev Anti Infect Ther. 2016;14(3):311-24. doi: 10.1586/14787210.2016.1138857. Epub 2016 Feb 5. Review.

PMID:
26848612
22.

Increase of efflux-mediated resistance in Pseudomonas aeruginosa during antibiotic treatment in patients suffering from nosocomial pneumonia.

Riou M, Avrain L, Carbonnelle S, El Garch F, Pirnay JP, De Vos D, Plésiat P, Tulkens PM, Van Bambeke F.

Int J Antimicrob Agents. 2016 Jan;47(1):77-83. doi: 10.1016/j.ijantimicag.2015.11.004. Epub 2015 Nov 26.

PMID:
26691019
23.

Editorial Commentary: Colistin and a New Paradigm in Drug Development.

Van Bambeke F, Tulkens PM.

Clin Infect Dis. 2016 Mar 1;62(5):559-60. doi: 10.1093/cid/civ968. Epub 2015 Nov 25. No abstract available.

PMID:
26607423
24.

Thrice-weekly temocillin administered after each dialysis session is appropriate for the treatment of serious Gram-negative infections in haemodialysis patients.

Vandecasteele SJ, Miranda Bastos AC, Capron A, Spinewine A, Tulkens PM, Van Bambeke F.

Int J Antimicrob Agents. 2015 Dec;46(6):660-5. doi: 10.1016/j.ijantimicag.2015.09.005. Epub 2015 Oct 9.

PMID:
26603304
26.

In Vitro Models for the Study of the Intracellular Activity of Antibiotics.

Buyck JM, Lemaire S, Seral C, Anantharajah A, Peyrusson F, Tulkens PM, Van Bambeke F.

Methods Mol Biol. 2016;1333:147-57. doi: 10.1007/978-1-4939-2854-5_13.

PMID:
26468107
27.

Correlation between cytotoxicity induced by Pseudomonas aeruginosa clinical isolates from acute infections and IL-1β secretion in a model of human THP-1 monocytes.

Anantharajah A, Buyck JM, Faure E, Glupczynski Y, Rodriguez-Villalobos H, De Vos D, Pirnay JP, Bilocq F, Guery B, Tulkens PM, Mingeot-Leclercq MP, Van Bambeke F.

Pathog Dis. 2015 Oct;73(7). pii: ftv049. doi: 10.1093/femspd/ftv049. Epub 2015 Jul 22.

29.
30.

In memoriam: William A. Craig.

Theuretzbacher U, Ambrose PG, MacGowan AP, Andes DR, Sörgel F, Derendorf H, Mouton JW, Drusano GL, Tulkens PM, Dudley MN, Cars O, Nation RL.

Antimicrob Agents Chemother. 2015;59(6):2971. doi: 10.1128/AAC.00849-15. Epub 2015 Apr 20. No abstract available.

31.

Validation of a HPLC-MS/MS assay for the determination of total and unbound concentration of temocillin in human serum.

Ngougni Pokem P, Miranda Bastos AC, Tulkens PM, Wallemacq P, Van Bambeke F, Capron A.

Clin Biochem. 2015 May;48(7-8):542-5. doi: 10.1016/j.clinbiochem.2015.02.006. Epub 2015 Feb 21.

PMID:
25712752
32.

Modulation of the activity of moxifloxacin and solithromycin in an in vitro pharmacodynamic model of Streptococcus pneumoniae naive and induced biofilms.

Vandevelde NM, Tulkens PM, Muccioli GG, Van Bambeke F.

J Antimicrob Chemother. 2015;70(6):1713-26. doi: 10.1093/jac/dkv032. Epub 2015 Feb 23.

PMID:
25712316
33.

Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients.

Chalhoub H, Tunney M, Elborn JS, Vergison A, Denis O, Plésiat P, Kahl BC, Van Bambeke F, Tulkens PM.

J Antimicrob Chemother. 2015 May;70(5):1596-8. doi: 10.1093/jac/dku551. Epub 2015 Jan 14. No abstract available.

PMID:
25587996
34.

Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration.

Laterre PF, Wittebole X, Van de Velde S, Muller AE, Mouton JW, Carryn S, Tulkens PM, Dugernier T.

J Antimicrob Chemother. 2015 Mar;70(3):891-8. doi: 10.1093/jac/dku465. Epub 2014 Nov 27.

PMID:
25433006
35.

Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes.

Buyck JM, Tulkens PM, Van Bambeke F.

Antimicrob Agents Chemother. 2015 Jan;59(1):258-68. doi: 10.1128/AAC.04011-14. Epub 2014 Oct 27.

36.

Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function.

Flanagan S, McKee EE, Das D, Tulkens PM, Hosako H, Fiedler-Kelly J, Passarell J, Radovsky A, Prokocimer P.

Antimicrob Agents Chemother. 2015 Jan;59(1):178-85. doi: 10.1128/AAC.03684-14. Epub 2014 Oct 20.

37.

Characterisation of a collection of Streptococcus pneumoniae isolates from patients suffering from acute exacerbations of chronic bronchitis: in vitro susceptibility to antibiotics and biofilm formation in relation to antibiotic efflux and serotypes/serogroups.

Vandevelde NM, Tulkens PM, Diaz Iglesias Y, Verhaegen J, Rodriguez-Villalobos H, Philippart I, Cadrobbi J, Coppens N, Boel A, Van Vaerenbergh K, Francart H, Vanhoof R, Liistro G, Jordens P, d'Odemont JP, Valcke Y, Verschuren F, Van Bambeke F.

Int J Antimicrob Agents. 2014 Sep;44(3):209-17. doi: 10.1016/j.ijantimicag.2014.05.016. Epub 2014 Jul 7.

PMID:
25123808
38.

Comparison of the antibiotic activities of Daptomycin, Vancomycin, and the investigational Fluoroquinolone Delafloxacin against biofilms from Staphylococcus aureus clinical isolates.

Siala W, Mingeot-Leclercq MP, Tulkens PM, Hallin M, Denis O, Van Bambeke F.

Antimicrob Agents Chemother. 2014 Nov;58(11):6385-97. doi: 10.1128/AAC.03482-14. Epub 2014 Aug 11.

39.

Penicillin susceptibility breakpoints for Streptococcus pneumoniae and their effect on susceptibility categorisation in Germany (1997-2013).

Imöhl M, Reinert RR, Tulkens PM, van der Linden M.

Eur J Clin Microbiol Infect Dis. 2014 Nov;33(11):2035-40. doi: 10.1007/s10096-014-2174-z. Epub 2014 Jun 15.

PMID:
24930041
40.

Study of macrophage functions in murine J774 cells and human activated THP-1 cells exposed to oritavancin, a lipoglycopeptide with high cellular accumulation.

Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F.

Antimicrob Agents Chemother. 2014;58(4):2059-66. doi: 10.1128/AAC.02475-13. Epub 2014 Jan 21.

41.

Development and validation of a high performance liquid chromatography assay for the determination of temocillin in serum of haemodialysis patients.

Miranda Bastos AC, Vandecasteele SJ, Tulkens PM, Spinewine A, Van Bambeke F.

J Pharm Biomed Anal. 2014 Mar;90:192-7. doi: 10.1016/j.jpba.2013.12.002. Epub 2013 Dec 12.

PMID:
24389461
42.

Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary.

Das D, Tulkens PM, Mehra P, Fang E, Prokocimer P.

Clin Infect Dis. 2014 Jan;58 Suppl 1:S51-7. doi: 10.1093/cid/cit618. Review.

PMID:
24343833
43.

Antibiotic activity against naive and induced Streptococcus pneumoniae biofilms in an in vitro pharmacodynamic model.

Vandevelde NM, Tulkens PM, Van Bambeke F.

Antimicrob Agents Chemother. 2014;58(3):1348-58. doi: 10.1128/AAC.01858-13. Epub 2013 Dec 16.

44.

Pharmacological characterization of 7-(4-(Piperazin-1-yl)) ciprofloxacin derivatives: antibacterial activity, cellular accumulation, susceptibility to efflux transporters, and intracellular activity.

Marquez B, Pourcelle V, Vallet CM, Mingeot-Leclercq MP, Tulkens PM, Marchand-Bruynaert J, Van Bambeke F.

Pharm Res. 2014 May;31(5):1290-301. doi: 10.1007/s11095-013-1250-x. Epub 2013 Dec 5.

PMID:
24306327
45.

A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms.

Bauer J, Siala W, Tulkens PM, Van Bambeke F.

Antimicrob Agents Chemother. 2013 Jun;57(6):2726-37. doi: 10.1128/AAC.00181-13. Epub 2013 Apr 9.

46.

Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects.

Ampe E, Delaere B, Hecq JD, Tulkens PM, Glupczynski Y.

Int J Antimicrob Agents. 2013 May;41(5):439-46. doi: 10.1016/j.ijantimicag.2013.01.009. Epub 2013 Mar 22.

PMID:
23523733
47.

Analysis of the membrane proteome of ciprofloxacin-resistant macrophages by stable isotope labeling with amino acids in cell culture (SILAC).

Caceres NE, Aerts M, Marquez B, Mingeot-Leclercq MP, Tulkens PM, Devreese B, Van Bambeke F.

PLoS One. 2013;8(3):e58285. doi: 10.1371/journal.pone.0058285. Epub 2013 Mar 7.

48.

Antibiotic activity against small-colony variants of Staphylococcus aureus: review of in vitro, animal and clinical data.

Garcia LG, Lemaire S, Kahl BC, Becker K, Proctor RA, Denis O, Tulkens PM, Van Bambeke F.

J Antimicrob Chemother. 2013 Jul;68(7):1455-64. doi: 10.1093/jac/dkt072. Epub 2013 Mar 13. Review.

PMID:
23485724
49.

Pharmacodynamic evaluation of the intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in a model of THP-1 human monocytes.

Buyck JM, Tulkens PM, Van Bambeke F.

Antimicrob Agents Chemother. 2013 May;57(5):2310-8. doi: 10.1128/AAC.02609-12. Epub 2013 Mar 11.

50.

Adverse drug reactions to antiretroviral therapy: prospective study in children in sikasso (mali).

Oumar AA, Diallo K, Dembélé JP, Samaké L, Sidibé I, Togo B, Sylla M, Tounkara A, Dao S, Tulkens PM.

J Pediatr Pharmacol Ther. 2012 Oct;17(4):382-8. doi: 10.5863/1551-6776-17.4.382.

Supplemental Content

Loading ...
Support Center